Resistant hypertension is typically defined as uncontrolled blood pressure (systolic and diastolic blood pressure >140 mmHg and >90 mmHg, respectively) despite treatment with at least three ...

A major factor contributing to this therapeutic failure is represented by resistant (or refractory) hypertension. The diagnosis of 'resistant hypertension' is very common in clinical practice ...

Other recent outcome studies document that resistant hypertension is not rare. In the Controlled ONset Verapamil INvestigation of Cardiovascular End Points trial (CONVINCE), [2] more than 16,600 ...

Hypertension, or high blood pressure, is a prevalent condition in the United States, affecting nearly half of adults and significantly increasing the risk of heart ...

They found that supplementing with B vitamins could reduce systolic blood pressure (the top number in a reading) by 6 to 13 ...

Q4 2024 Management View CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and ...

MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal Research Laboratory at Mayo Clinic.

Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent US 12,186,299 dated Jan. 7, 2025, Compositions And Methods For Treating ...

Dr. Gilbert J. Zoghbi, MD. FACC, FSCAI discusses renal denervation therapy, a new FDA-approved treatment for resistant hypertension, now available at Baptist facilities.

This past year was important for the development of lorundrostat, and the entire Mineralys team contributed to the execution of our clinical ...